Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma

BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2002-06, Vol.94 (11), p.2930-2934
Hauptverfasser: Porembska, Zofia, Skwarek, Anna, Mielczarek, Magdalena, Barańczyk‐Kuźma, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2934
container_issue 11
container_start_page 2930
container_title Cancer
container_volume 94
creator Porembska, Zofia
Skwarek, Anna
Mielczarek, Magdalena
Barańczyk‐Kuźma, Anna
description BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society. DOI 10.1002/cncr.10563 The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.
doi_str_mv 10.1002/cncr.10563
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71894986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71894986</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</originalsourceid><addsrcrecordid>eNp90E1LwzAYwPEgipvTix9ActGDUM1L07RHKb7BUPAFditplsxIm8wkdezbm7mBN09JyI_ngT8ApxhdYYTItbTSpxsr6B4YY1TxDOGc7IMxQqjMWE5nI3AUwmd6csLoIRhhgjGjJR6D2avyQw-FXxgrgoJCRvNt4hoaC5cuxDCkHyk62DtrovPGLqDTcCmiUTYGuDLxA0rXOa9kTEwKL411vTgGB1p0QZ3szgl4v7t9qx-y6fP9Y30zzSRljGblvJBtqwQuCKJEoTJH5ZzOGaEFI1hUivKq1Ywy0eYtw5prWmCuCy4I5kpqOgEX27lL774GFWLTmyBV1wmr3BAajssqr8oiwcstlN6F4JVult70wq8bjJpNx2bTsfntmPDZburQ9mr-R3fhEjjfARFSHu2FlSb8OVrwnCGeHN66lenU-p-VTf1Uv2yX_wCCqouL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71894986</pqid></control><display><type>article</type><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</creator><creatorcontrib>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</creatorcontrib><description>BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society. DOI 10.1002/cncr.10563 The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.10563</identifier><identifier>PMID: 12115381</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - enzymology ; Adenocarcinoma - secondary ; Adenocarcinoma - surgery ; Adult ; Aged ; arginase ; Arginase - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; colorectal liver metastases ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; human colorectal carcinoma ; Humans ; Liver Neoplasms - enzymology ; Liver Neoplasms - secondary ; Liver Neoplasms - surgery ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - enzymology ; Neoplasm Recurrence, Local - secondary ; Neoplasm Recurrence, Local - surgery ; Postoperative Care ; Preoperative Care ; Prognosis ; serum marker ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Cancer, 2002-06, Vol.94 (11), p.2930-2934</ispartof><rights>Copyright © 2002 American Cancer Society</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</citedby><cites>FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.10563$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.10563$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13674507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12115381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Porembska, Zofia</creatorcontrib><creatorcontrib>Skwarek, Anna</creatorcontrib><creatorcontrib>Mielczarek, Magdalena</creatorcontrib><creatorcontrib>Barańczyk‐Kuźma, Anna</creatorcontrib><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society. DOI 10.1002/cncr.10563 The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</description><subject>Adenocarcinoma - enzymology</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>arginase</subject><subject>Arginase - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>colorectal liver metastases</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>human colorectal carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - enzymology</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - enzymology</subject><subject>Neoplasm Recurrence, Local - secondary</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Postoperative Care</subject><subject>Preoperative Care</subject><subject>Prognosis</subject><subject>serum marker</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90E1LwzAYwPEgipvTix9ActGDUM1L07RHKb7BUPAFditplsxIm8wkdezbm7mBN09JyI_ngT8ApxhdYYTItbTSpxsr6B4YY1TxDOGc7IMxQqjMWE5nI3AUwmd6csLoIRhhgjGjJR6D2avyQw-FXxgrgoJCRvNt4hoaC5cuxDCkHyk62DtrovPGLqDTcCmiUTYGuDLxA0rXOa9kTEwKL411vTgGB1p0QZ3szgl4v7t9qx-y6fP9Y30zzSRljGblvJBtqwQuCKJEoTJH5ZzOGaEFI1hUivKq1Ywy0eYtw5prWmCuCy4I5kpqOgEX27lL774GFWLTmyBV1wmr3BAajssqr8oiwcstlN6F4JVult70wq8bjJpNx2bTsfntmPDZburQ9mr-R3fhEjjfARFSHu2FlSb8OVrwnCGeHN66lenU-p-VTf1Uv2yX_wCCqouL</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Porembska, Zofia</creator><creator>Skwarek, Anna</creator><creator>Mielczarek, Magdalena</creator><creator>Barańczyk‐Kuźma, Anna</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</title><author>Porembska, Zofia ; Skwarek, Anna ; Mielczarek, Magdalena ; Barańczyk‐Kuźma, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3553-8d6cbbea162032e08408d3d5236521a9e379bf535ab4b51f7f3617f67a217ecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adenocarcinoma - enzymology</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>arginase</topic><topic>Arginase - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>colorectal liver metastases</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>human colorectal carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - enzymology</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - enzymology</topic><topic>Neoplasm Recurrence, Local - secondary</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Postoperative Care</topic><topic>Preoperative Care</topic><topic>Prognosis</topic><topic>serum marker</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Porembska, Zofia</creatorcontrib><creatorcontrib>Skwarek, Anna</creatorcontrib><creatorcontrib>Mielczarek, Magdalena</creatorcontrib><creatorcontrib>Barańczyk‐Kuźma, Anna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Porembska, Zofia</au><au>Skwarek, Anna</au><au>Mielczarek, Magdalena</au><au>Barańczyk‐Kuźma, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>94</volume><issue>11</issue><spage>2930</spage><epage>2934</epage><pages>2930-2934</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society. DOI 10.1002/cncr.10563 The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12115381</pmid><doi>10.1002/cncr.10563</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2002-06, Vol.94 (11), p.2930-2934
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_71894986
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adenocarcinoma - enzymology
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Adult
Aged
arginase
Arginase - blood
Biological and medical sciences
Biomarkers, Tumor - blood
colorectal liver metastases
Colorectal Neoplasms - enzymology
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Female
Gastroenterology. Liver. Pancreas. Abdomen
human colorectal carcinoma
Humans
Liver Neoplasms - enzymology
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - enzymology
Neoplasm Recurrence, Local - secondary
Neoplasm Recurrence, Local - surgery
Postoperative Care
Preoperative Care
Prognosis
serum marker
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
title Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A57%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20arginase%20activity%20in%20postsurgical%20monitoring%20of%20patients%20with%20colorectal%20carcinoma&rft.jtitle=Cancer&rft.au=Porembska,%20Zofia&rft.date=2002-06-01&rft.volume=94&rft.issue=11&rft.spage=2930&rft.epage=2934&rft.pages=2930-2934&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.10563&rft_dat=%3Cproquest_cross%3E71894986%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71894986&rft_id=info:pmid/12115381&rfr_iscdi=true